Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
Single-Port Surgery Changes the Landscape in Prostate Cancer Treatment
Bertram Yuh, MD, MISM, MSHCPM, discussed how single-port robotic surgery has changed treatment paradigms for patients with prostate cancer.
A Deep Dive Into the Evolving Landscape of Prostate Cancer
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
GU Oncologists Anticipate Earlier Role of Lutetium-177 PSMA-617 in Prostate Cancer
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.
Talazoparib/Enzalutamide Combo Offers Significant Survival Benefits in Prostate Cancer
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.